Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ...
Teva, Sanofi say bowel disease drug met primary targets
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...
biopharma-reporter12h
Teva and Sanofi’s IBD drug hits Phase 2 targets
The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those ...
globes.co.il11h
Teva jumps sharply on bowel disease drug results
Teva reported that the trial met its primary endpoints in ulcerative colitis and Crohn's disease, the most common forms of ...
pharmaphorum13h
Teva, Sanofi score well with anti-TL1A drug in IBD test
The TL1A drug would serve as a companion to Sanofi and partner Regeneron's multibillion-dollar blockbuster Dupixent ...
Teva, Sanofi say drug to treat IBD met primary targets
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...
FierceBiotech12h
Sanofi, Teva look to 'next frontier' in IBD treatment after TL1A antibody hits mark in midstage trial
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...
Hosted on MSN6h
Teva, Sanofi Say Inflammatory Bowel Disease Drug Study Meets Primary Endpoints
US affiliate and partner Sanofi (SNY) said Tuesday that a phase 2b study of Teva's investigational duvakitug drug to treat ulcerative colitis and Crohn's disease met its primary endpoints. Ulcerative ...
Teva, Sanofi report RELIEVE UCCD Phase 2b study met primary endpoints
Sanofi (SNY) and Teva Pharmaceuticals (TEVA) announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ...
TMCnet13h
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
We are thrilled to welcome Dr. Feagan to our Clinical Advisory Board,” said JD Finley, Chief Executive Officer of Palisade Bio. “Dr. Feagan’s extensive research experience in CD and UC, along with his ...